Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3658589 | 0.88 | ALDH1A1 (0.49) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL3660316 | 0.87 | ALDH1A1 (0.51) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL3657694 | 0.84 | HTT (0.59) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL3658650 | 0.82 | HTT (0.62) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL9450633 | 0.82 | HTT (0.58) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL10543134 | 0.82 | HTT (0.58) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL9450606 | 0.81 | HTT (0.60) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL3660873 | 0.81 | CYP1A2 (0.49) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL9450640 | 0.80 | PRSS1 (0.39) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL9450639 | 0.80 | PRSS1 (0.39) | HTTSMN1; SMN2ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030719-A1 | Cis-3,5-disubstituted-dihydro-furan-2-ones and the preparation and use thereof | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-02-09 | — | — | US | disclosed |
| WO-2005014565-A2 | CIS-3,5-DISUBSTITUTED-DIHYDRO-FURAN-2-ONES AND THE PREPARATION AND USE THEREOF | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030719-A1 | Cis-3,5-disubstituted-dihydro-furan-2-ones and the preparation and use thereof | CBR3, CYP4F3, DHODH | HTT 2684/4885SMN1; SMN2 3390/4885ALDH1A1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.